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Background: Neutrophilic inflammation causes lung damage in cystic fibrosis (CF). Recent data from animal models suggest that the migration of
blood monocytes into the airway supports neutrophil-mediated tissue injury. CF may therefore be associated with increased airway levels of
chemoattractants for pro-inflammatory monocytes. In this study, we sought to assess the levels of monocyte chemoattractants CCL2 and CX3CL1
in the blood and airways of patients with CF, and expression of their respective receptors CCR2 and CX3CR1 on blood monocytes.
Methods: Blood was obtained from 32 CF patients and 25 healthy controls. Induced sputum was obtained from a further 24 CF patients and 17
healthy controls. Expression of CCR2 and CX3CR1 on CD14++CD16− and CD14+CD16+ blood monocytes was determined by flow cytometry.
CCL2 and CX3CL1 levels in blood and induced sputum were determined by ELISA.
Results: Total blood monocyte concentration was not different between CF and controls. CCR2 was absent, and CX3CR1 higher on CD14+CD16+
monocytes from both CF and controls when compared with expression on CD14++CD16− cells. There was no difference in expression of chemokine
receptors by either monocyte subpopulation between CF and controls. Blood CCL2, but not CX3CL1, was increased in CF patients (p = 0.006).
Similarly, CF was associated with increased induced sputum CCL2, but not CX3CL1 (190.6 vs. 77.3pg/mL; p = 0.029).
Conclusion: CCL2, but not CX3CL1 is increased in the airway and blood of CF patients. Blood monocytes from CF patients are phenotypically
competent to respond to CCL2, since they express normal levels of CCR2.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: CCL2; CX3CL1; Monocytes; Cystic fibrosis; Induced sputum1. Introduction
Increased numbers of airway neutrophils are a characteristic
feature of cystic fibrosis (CF), and contribute significantly to
irreversible airway damage and loss of lung function [1,2]. Recent
data from a murine model suggest that recruitment of pro-⁎ Corresponding author. Centre of Paediatrics, Institute of Cell and Molecular
Science, Barts and the London School of Medicine and Dentistry, Queen Mary
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doi:10.1016/j.jcf.2008.09.009inflammatory blood monocytes into the airway synergistically
enhances neutrophil transmigration into the lung [3]. From these
data, we hypothesised that monocyte transmigration into the
airway is increased in CF [4]. As a first step in testing this
hypothesis, we sought evidence for increased levels of monocyte
chemoattractants in the blood and airways of patients with CF. The
current paradigm for blood monocyte migration into the lung is
that CCL2, formally called monocyte chemoattractant protein-1,
increases the tissue migration of monocytes with a propensity to
initiate and sustain inflammation [5]. CX3CL1, formerly termed
fractalkine, in contrast, tends to control themigration ofmonocytes
that will become tissue macrophages and dendritic cells in non-
inflamed tissue [5]. CCL2 has been detected in the blood andd by Elsevier B.V. All rights reserved.
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whether monocyte chemoattractant chemokines are increased in
CF, since no study to date has included normal controls.
Recruitment of blood monocytes into tissue depends on the
expression of chemokine receptor on monocyte subsets. In
humans, expression of the receptors for monocyte chemoat-
tractant chemokines is not the same for all subpopulations of
blood monocytes. Two important populations of blood mono-
cytes are i) the major population of “classical” blood
monocytes, which show high levels of cell surface CD14 and
no CD16 expression (CD14++CD16− monocytes), and ii) a
“minor” population ofmonocytes, characterised by low level CD14
and co-expression of CD16 (CD14+CD16+ monocytes [8],
reviewed in Ziegler-Heitbrock [9]). Studies in the mouse model
have shown that the homologues of both subpopulations of
monocytes have the capacity to migrate to sites of inflammation
[10–13]. Migration studies in man have demonstrated that the
CD14+CD16+ subpopulation has a high ability for transendothelial
reverse migration [14], and that these cells preferentially respond to
CX3CL1 [15]. In contrast, CD14++CD16− monocytes, migrate
towards CCL2 [16]. This differential migration behaviour of the
two types of monocytes in normal humans corresponds to the
differential pattern of chemokine receptors; CD14+CD16+ mono-
cytes lack CCR2 and express high levels of CX3CR1, while the
CD14++CD16− monocytes are CCR2 positive and show low
levels of CX3CR1 [15,16]. To establish whether blood monocytes
are phenotypically competent to respond to CCL2 or CX3CL1 in
the CF airway, therefore requires receptor expression on both
subpopulations to be assessed.
In this study, we sought evidence for increased monocyte
chemoattractant activity in the CF airway. We first aimed to
determine the levels of blood CCL2 and CX3CL1, and the pattern
of receptor expression for these chemokines on blood monocytes.
Second, we aimed to confirm findings using induced sputum
samples. To assess the relevance of changes in CX3CL1 and
CCL2, we also measured chemokine receptor expression on
CD14+CD16+ and CD14++CD16− blood monocytes.
2. Methods
2.1. Subjects
CF patients were recruited in tertiary care. Diagnosis of CF was
by an elevated sweat chloride level, and all patients had
confirmatory testing for CF gene mutations. CF patients were
recruited either during a routine outpatient visits, or during a
hospital admission for intravenous antibiotic therapy. Clinical
details were obtained from a review of the clinical notes. Controls
were recruited from healthy volunteers. The studywas approved by
the local ethics committee and required written consent for adults,
and assent and written parental consent for children. We initially
compared the absolute counts of different monocyte subpopula-
tions, serum CCL2 and CX3CL1, chemokine receptor expression
for CCL2 and CX3CL1 onmonocytes subpopulations between CF
and healthy control groups. To confirm that changes in chemokines
in the blood reflected changes in the airway, we then measured the
concentrations of CCL2 and CX3CL1 in induced sputum samples.2.2. Blood monocyte count
100µL of EDTA whole blood was stained with fluorescent-
labeled antibodies for CD14, CD16 and HLADR using CD16
PE (BD Biosciences, Oxford), MY4-FITC (Beckman Coulter,
High Wycombe), and HLADR-PC5 (Beckman Coulter) and
incubated for 20min at 4°C. Red cells were lysed by 3mL of
ammonium chloride based erythrocyte lysis buffer incubated at
room temperature for 20min. 100µL of flow-count beads
(Beckman Coulter, PN 7507992-E) was added to determine
absolute counts. Monocytes were characterised as previously
reported [8,9], using flow cytometry (FACSCalibur BD) and the
gating strategy outlined in Fig. 1.
2.3. CCR2 expression on blood monocytes
100μL of EDTAwhole blood was washed three times with
1mL of phosphate buffer solution (PBS) with 2% fetal calf
serum (FCS) at 400g for 5min. Cells were incubated at 4°C for
20min with CD16 FITC (Dakocytomation, Ely), CD14 APC
(Beckman Coulter), HLADR PerCP (BD Biosciences), to
define CD14++CD16− and CD14+CD16+ subsets. CCR2
expression on the two monocyte subsets was determined using
CCR2 PE (R&D Systems), and non specific fluorescence was
determined using the isotype control for CCR2 PE; IgG2b PE
(R&D systems). Red cells were lysed by adding 3mL of
ammonium chloride based erythrocyte lysis buffer incubated at
room temperature for 20min. Monocyte subsets were identified
as described in Fig. 1. The median fluorescence intensity for
CCR2 expression on CD14++CD16− and CD14+CD16+
monocytes was determined in CF and controls by subtracting
the fluorescence obtained with the respective isotype controls
(Fig. 2 A,B).
2.4. CX3CR1 expression on blood monocytes
100μL of whole EDTA blood was incubated at 4°C for 20min
with CD16 PE (BDBiosciences), CD14APC (BeckmanCoulter),
HLADR PerCP (BD Biosciences) and with either CX3CR1 FITC
(Medical andBiological laboratoriesCo. LTD), or 20µL rat IgG2b
FITC (isotype control for CX3CR1) (Medical and Biological
Laboratories Co. LTD). Cells were washed with 1mL of PBSwith
2% FCS at 400g for 5min. Red cells were lysed by adding 3mL of
ammonium chloride based erythrocyte lysis buffer incubated at
room temperature for 20min.Monocyte subsets were identified as
described above, apart from the use of a different CD16
monoclonal antibody. The median fluorescence intensity for the
CX3CR1 for CD14++CD16− and CD14+CD16+ subsets in CF
and controls was determined by subtracting the fluorescence
obtained with the respective isotype control (Fig. 2 A,B).
2.5. Blood CCL2 and CX3CL1
Blood CCL2 was determined using the human CCL2 ELISA
kit (BD Biosciences, Oxford) according to the manufacturer's
instructions. Samples were initially diluted 1:10 for analysis.
Repeat analysis was carried out on undiluted serum samples if
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determined using the human/CX3CL1 kit (R&D systems,
Abingdon) according to the manufacturer's instructions. Samples
were initially diluted 1:10 for analysis and repeat analysis was
carried out on undiluted samples if no CX3CL1 was detected.
2.6. Induced sputum CCL2 and CX3CL1
Induced sputum (IS) was obtained using 5.4% hypertonic
saline via an ultrasonic nebuliser (Multisonic Profi, Schill) for a
maximum of 15min [17]. The IS sample was homogenised with
dithiothreitol (DTT, Calbiochem, California, USA) (volume
equivalent to 4 times the weight of the IS sample) and washed
with PBS (i.e. the same volume as DTT). The resulting
supernatant was stored at− 70°C for ELISA analysis as described
for serum samples. We established that DTT did not affect IS
chemokine concentrations.
2.7. Statistics
Data are presented as median and range. Data were compared
using the Mann–Whitney test. Correlations were determined by
Spearman rank correlation (Rs). Statistical analyses were
performed using SPSS for Windows Version 10 (SPSS Inc,
Chicago, IL, USA). A p value b 0.05 was considered statistically
significant.
3. Results
For blood variables, we recruited 36 CF patients and 26
healthy controls. CF patients tended to be younger and had
lower FEV1 compared with controls (Table 1). 17/36 CF
patients for blood sampling had an exacerbation of respiratory
symptoms at the time of sampling, 13 patients were receiving
regular inhaled steroids (Table 1). Four patients were receiving
oral prednisolone and were excluded per protocol from the
analysis. Data from a healthy control with active hay fever and
receiving antihistamines at the time of study was also excluded.
Not all subjects had all blood variables assessed due to limited
sample volumes, and the timing of sampling.
24 CF patients and 17 healthy controls were recruited for
sputum induction. CF patients undergoing sputum induction
also had lower FEV1 compared with controls (Table 2). 10/24
CF patients had an exacerbation of respiratory symptoms at the
time of sampling, 3 were receiving intravenous antibiotic
treatment, and a positive microbiological culture was obtained
from 11 (Table 2). 14 CF patients were receiving regular inhaled
steroids and none was receiving oral prednisolone.Fig. 1. Determination of absolute numbers of blood monocytes by flow
cytometry. Peripheral blood leucocytes are identified using flow cytometry by
light scatter characteristics. Mononuclear cells are identified in gate R2 (A). Gate
R3 (A) is placed around flow-count beads. Events in R2 are gated onto a CD14/
HLA DR dot plot. Gate R4 (B) defines events that express HLA DR and CD14.
Events in R4 are then given in the CD14 vs. CD16 dot plot (C). CD14++CD16−
monocytes are represented in R6 and CD14+CD16+ monocytes in gate R5. The
absolute count is derived from the number of flow-count beads represented in
gate R8.
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Table 1
Demographics of CF patients and controls used to assess blood variables
CF Controls
Total recruited (n) 32 25
Male: Female (n) 16:16 13:12
Age (year) 16 (4 to 34) 24 (7 to 35)
Forced expiratory volume in 1 s
(FEV1% predicted)
62 (30 to 99) 82.5 (72 to 110)
Clinical respiratory exacerbation (n) 17 Not applicable
Data are given as median (range) unless indicated.
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There were no differences in the total blood monocyte count
between CF and controls. Furthermore, there was no differences
in total CD14++CD16−, and total CD14+CD16+ cell counts
(Table 3). There was no association between total monocyte count
and subject age, no association between total monocyte count and
FEV1% predicted for both CF and controls, and no association
between the absolute numbers of the CD14++CD16− and
CD14+CD16+ monocytes and these variables (data not shown).
3.2. Blood monocyte CCR2 and CX3CR1 expression
Consistent with previous reports [18], CD14++CD16− mono-
cytes from both CF and controls expressed CCR2 (Fig. 2A),
whereas CD14+16+ monocytes did not express this receptor
(Fig. 2B). There was no difference in CCR2 expression by
CD14++CD16− cells between CF patients (n = 14) and controls
(n = 15) (Table 3, Fig. 2A). Expression of CX3CR1 was highest
on CD14+CD16+ monocytes, with no difference in CX3CR1
expression between CF (n = 12) and controls (n = 13) for either
monocyte subset (Table 3, Fig. 2B).
3.3. Blood CCL2 levels
Blood CCL2 was increased in CF (n = 14) compared with
controls (n = 15) (1081 (149.8 to 2340) vs. 295.5 (40.07 to 1301)
respectively; p = 0.006, Fig. 3A). CCL2 was not associated with
age, or FEV1% predicted in the CF group (not significant by
Spearman Rank test), and there was no difference in serum CCL2
between CF patients with and without a clinical exacerbation.
3.4. Blood CX3CL1 levels
There was no difference in blood CX3CL1 between the CF
group (n = 14) and healthy controls (n = 15) (Median (range)
25.5 (11 to 75.5) vs. 16.00 (8.5 to 44) pg/mL, p = 0.15, Fig. 3B).Fig. 2. A) Representative histograms of CCR2 and CX3CR1 expression on CD14++C
open histograms denote non-specific background staining and specific antibody stain
between specific staining (open histogram) and non-specific staining (shaded). Bot
monocytes but there was no difference between the groups. B) Representative histogr
CF and control subjects. The shaded histogram and open histograms denote non-sp
fluorescence intensity is calculated from the difference between specific staining (o
expressed on both CF and control CD14+CD16+ monocytes. There was no differen3.5. Induced sputum CCL2 levels
CCL2 levels in IS were increased in the CF group (n = 24)
compared with controls (n = 17) (190.6 (0 to 7551) pg/mL vs.
77.31pg/mL (0 to 504.5), respectively, p = 0.029, Fig. 4A).
CCL2 in IS was not associated with age, or FEV1% predicted in
the CF group, and there was no difference in IS CCL2 between
CF patients with and without an exacerbation.
3.6. Induced sputum CX3CL1 levels
Therewas no difference in ISCX3CL1 betweenCF (n= 24) and
controls (n = 17) (17.68 (0 to 36.3) vs. 18.25 (16.8 to 24.73), p =
0.36, Fig. 4B).
4. Discussion
The major finding of this study is that CCL2, a potent
chemoattractant for blood monocytes to migrate into inflamed
tissues [5], is increased in the blood and in the airway of CF
patients, and that CD14++CD16− blood monocytes from CF
patients express normal levels of CCR2, the receptor for CCL2
[19]. Levels of CX3CL1, a chemoattractant responsible for the
constitutive migration of monocytes into non-inflamed tissues
[5], are not increased in the blood or airway of CF patients.
There was no difference in the expression of CX3CR1 by blood
monocytes, the receptor for CX3CL1, between CF and controls.
CCL2 has been previously measured in CF, but no study has
compared CCL2 between CF and controls. Augarten et al. [6]
reported increased blood CCL2 in 25 patients who carried two
mutations associated with a pathological sweat test and pancreatic
insufficiency, compared to 11 compound heterozygote patients
who carried one mutation known to cause mild disease with
borderline or normal sweat test and pancreatic sufficiency [6].
Airway CCL2 was not assessed in the study of Augarten et al. [6],
howeverMcAllister et al., [7] screened 18 cytokines in the sputum
of 11 adults with CF patients and found that that CCL2was higher
at day 1 of hospitalisation for an exacerbation compared with day
20. The present study, by including normal controls, definitively
shows that CCL2 is increased in the blood and airway of patients
with CF, and are compatible with the recent evidence from animal
models that transmigration ofmonocytes into the airway amplifies
neutrophilic airway inflammation [3]. Although it remains to be
determined whether elevated airway CCL2 in CF increased
monocyte migration into the airway, the levels of CCL2 detected
in IS samples fromCFpatients (up to 100pg/mL), are similar to the
concentration reported to stimulate the migration of human
peripheral blood monocytes in vitro [20]. From our results we
hypothesise that IS samples in CF will contain an increasedD16− blood monocytes from CF and control subjects. The shaded histogram and
ing respectively. Median fluorescence intensity is calculated from the difference
h CCR2 and CX3CR1 are expressed on both CF and control CD14++CD16−
ams of CCR2 and CX3CR1 expression on CD14+CD16+ blood monocytes from
ecific background staining and specific antibody staining respectively. Median
pen histogram) and non-specific staining (shaded). CX3CR1 but not CCR2 is
ce between the groups in CX3CR1 expression.
Fig. 3. A) Dot plot showing concentrations of blood CCL2, formally called
monocyte chemoattractant protein-1, in cystic fibrosis patients compared with
healthy controls. The horizontal bar represents median value. ⁎pb0.01 by Mann
Whitney test. B) Concentrations of CX3CL1, formally called fractalkine, in
blood from cystic fibrosis patients compared with healthy controls. The
horizontal bar represents median value. There is no significant difference
between the groups by Mann Whitney Test.
Table 2
Subject demographics for induced sputum, and CCL2, and CX3CL1
CF Controls p value by Mann
Whitney test
Total recruited (n) 24 17
Male: Female (n) 9:15 9:8
Age (year) 13 (7 to 47) 22 (9 to 50)
FEV1% predicted 69 (46 to 97) 94 (81 to 113)
Respiratory
exacerbation
10 Not applicable
Positive
microbiological
culture
11 (7 Pseudomonas
aeruginosa, 4
Staphylococcus
aureus, 1 H
influenzae, 1
Mycobacterium
abscesses, 1
Aspergillus)
Not applicable
Sputum
CCL2 (pg/mL)
190.6
(0 to 7551)
77.31
(0 to 504.5)
0.029
Sputum
CX3CL1 (pg/mL)
17.68
(0 to 36.3)
18.25
(16.8 to 24.7)
0.36
Data are given as median (range) unless indicated.
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suggestive of recently transmigrated cells. One method to identify
recently transmigrated monocytes in the airway is by their
relatively small size comparedwith resident alveolarmacrophages.
Indeed, an increased proportion of “small” airway macrophages
has been found in the airways of adults with chronic obstructive
airways disease (COPD) [21]. We found no association between
lung function and CCL2 in CF patients. This does not rule out a
major role of CCL2 in CF-associated lung damage since changes
in lung function may lag significantly behind tissue-damaging
airway inflammation. Similarly, although no association between
induced sputum CCL2 and lung function has been reported in
COPD [22], increased levels of CCL2 in COPD have been
interpreted as indicating that monocyte transmigration contributes
to the inflammatory load in the airway [22]. In contrast with the
longitudinal study ofMcAllister et al. [7], we found thatCCL2was
not increased in CF patients during an exacerbation when
compared to clinically stable CF patients. However, the cross
sectional nature of the present study, may not have provided
sufficient power to detect subtle changes during exacerbations.Table 3
Blood monocyte counts, CCR2 and CX3CR1 expression on CD14++CD16− and C
Blood monocyte subset CD14++CD16− Cell count (μL blood) median (range)
CCR2 (median fluorescence intensity)
CX3CR1 (median fluorescence intensity)
Blood monocyte subset CD14+CD16+ Cell count (μL blood) median (range)
CCR2 (median fluorescence intensity)
CX3CR1 (median fluorescence intensity)
Blood CCL2 (pg/mL)
Blood CX3CL1 (pg/mL)
Data are given as median and (range) unless indicated.
⁎⁎pb0.0001 compared with CD14++CD16− monocytes by Mann Whitney test.The ability of airway chemoattractants to recruit blood
monocytes is, in part, determined by the expression of chemokine
receptors on circulating cells. Although monocyte function is
abnormal inCF [23], we found no difference inCCR2 expression,
the receptor for CCL2, by CD14++CD16− monocytes between
CF and controls, and no difference in the number of these cells in
the blood. In order not to overlook significant changes in
chemokine receptor expression in a clinically significant mono-
cyte subset, we also assessed chemokine receptor expression on
CD14+CD16+ monocytes — a subset can give rise to potent
dendritic cells [9,14]. Compatible with previous studies [18], weD14+CD16+ monocytes, and blood CCL2 and CX3CL1
CF Controls p value
426 (79 to 982) (n=29) 362 (140 to 765) (n=21) 0.35
21.45 (4.8 to 156.4) (n=14) 22.85 (4.2 to 82.3) (n=15) 0.84
51.77 (17.1 to 92.8) (n=12) 31.49 (17.8 to 78.2) (n=13) 0.24
36 (8 to 117) (n=29) 35 (2 to 98) (n=21) 0.31
Not expressed (n=14) Not expressed (n=15) Not done
168.6** (83.7 to 242.4) (n=12) 198.8** (34.9 to 274.1) (n=13) 0.38
1081 (149.8 to 2340) (n=14) 295.5 (40.0 to 1301) (n=15) 0.006
25.5 (11 to 75.5) (n=14) 16.00 (8.5 to 44) (n=15) 0.15
Fig. 4. A) Dot Plot showing concentrations of CCL2 in induced sputum of cystic
fibrosis patients compared with healthy controls. The horizontal bar represents
the median value. ⁎pb0.05 by Mann Whitney test. B) Concentrations of
CX3CL1 in sputum of cystic fibrosis patients compared with healthy controls.
The horizontal bar represents median value. There is no significant difference
between the groups by Mann Whitney test.
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CD14++CD16−monocytes) expressed higher levels of CX3CR1
(the receptor for CX3CL1). Increased blood CX3CR1 has been
reported in atopic asthma [24], but it has not been previously
measured in CF. Since we found no increase in CX3CL1 in CF
patients, it is unlikely that CF airway inflammation is associated
with increased activation of the CX3CR1/CX3CL1 axis. Indeed
our results are compatible with the paradigm that the CX3CR1/
CX3CL1 axis is responsible for the transmigration of blood
monocytes into non-inflamed tissues [19].
In conclusion, we have confirmed our hypothesis that CCL2 is
increased in the airway and blood of patients with CF. Increased
CCL2 in CF is associated with normal levels of expression of the
CCL2 receptor (CCR2) on CD14++ monocytes. Our data are
compatible with the hypothesis that that blood monocyte
migration into the airway contributes to airway inflammation in
CF.
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